Journal of Oral Medicine and Pain

Korean Academy of Orofacial Pain and Oral Medicine (대한안면통증구강내과학회)
권호 표지

A Study on Clinical Features and Pharmacologic Treatment Outcomes of Patients with Trigeminal Neuralgia

삼차신경통의 임상 소견과 약물 치료에 관한 연구

  • Ko, Yu-Jeong (Department of Oral Medicine, School of Dentistry, Kyungpook National University) ;
  • Kim, Kyun-Yo (Department of Oral Medicine, School of Dentistry, Kyungpook National University) ;
  • Hur, Yun-Kyung (Department of Oral Medicine, School of Dentistry, Kyungpook National University) ;
  • Choi, Jae-Kap (Department of Oral Medicine, School of Dentistry, Kyungpook National University)
  • 고유정 (경북대학교 치의학전문대학원 구강내과학교실) ;
  • 김균요 (경북대학교 치의학전문대학원 구강내과학교실) ;
  • 허윤경 (경북대학교 치의학전문대학원 구강내과학교실) ;
  • 최재갑 (경북대학교 치의학전문대학원 구강내과학교실)
  • Published : 2009.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Trigeminal neuralgia is defined "a sudden, usually unilateral, severe, brief, stabbing, recurrent pain in the distribution of one or more branches of the fifth cranial nerve". The initial treatment of choice for trigeminal neuralgia is medical therapy. In patients with medically intractable pain or intolerable medication side effects, invasive therapeutic approaches are often necessary. Based on the amount of evidence and estimated efficacy, carbamazepine is the drug of choice in the management of trigeminal neuralgia. In case of insufficient or no response to carbamazepine, second-line drugs can be added. In this study, the author tried to review and analyzed the cases of 90 patients whom had visited for treatment of trigeminal neuralgia at the Department of Oral Medicine, Kyungpook National University Hospital from 2003 to 2008. The results were as follows: 1. Trigeminal neuralgia was significantly more common with advancing age, and nearly twice as common in women than men (ratio of 2.1:1) 2. The maxillary branch of the trigeminal nerve involved most often (51.1%), and the right side of the face is affected more commonly than the left (ratio of 2.9:1). 3. 85(94.4%) patients had experiences visiting medical or dental specialties before being referred to the Department of Oral Medicine. 4. 40(44.4%) patients with trigeminal neuralgia had systemic diseases. 5. Treatment with carbamazepine monotherapy was satisfactory initially in 69(76.7%) the patients, and the mean daily dose of carbamazepine was 402.9mg. On the other hand, 16(17.8%) patients expressed effectiveness after combination therapy of carbamazepine and other drugs. 6. Of the 69 patients who had a good initial response to carbamazepine monotherapy, 18 patients became resistant, so that combination therapy of carbamazepine and other drugs were necessary. 7. 54(60%) patients developed side effects such as dizziness, drowsiness, nausea, vomiting, blood dyscrasias, skin rash and constipation, and 11 of the patients decided to stop tmedicaion due to side effects.

2003년부터 2008년까지 경북대학교병원 구강내과를 내원한 삼차신경통 환자 90명의 임상 소견 및 약물 치료에 대한 결과를 분석하여 다음과 같은 결론을 얻었다. 1. 삼차신경통 환자는 40대 이상이 94.4%를 차지하였고 남녀비가 1:2.1로 여성에서 거의 2배 정도 호발하였다. 2. 삼차신경의 상악분지에 단독으로 이환된 경우가 51.1%로 가장 많았고 좌우비가 1:2.9로 우측에 더 자주 발생하였다. 3. 85명(94.4%)의 환자가 경북대학교병원 구강내과에 내원하기 전 삼차신경통을 치료하기 위해 다른 의료기관을 내원한 경험이 있었다. 3. 40명(44.4%)의 환자가 현재 치료 중인 전신질환을 가지고 있었다. 4. Carbamazepine 단독 투여로 69명(76.7%)의 환자가 효과를 나타내었으며 이 때 사용된 Carbamazepine의 일일 용량은 평균 402.9mg이었다. 반면에 16명(17.8%)의 환자는 Carbamazepine과 다른 약물을 복합 투여하여 효과를 나타내었고 사용된 Carbamazepine 일일 용량은 평균 618.8mg이었으며 가장 많이 사용된 병용 약물은 Baclofen이었다. 나머지 5명(5.6%)의 환자는 Carbamazepine으로 효과를 얻지 못했다. 5. Carbamazepine 단독 투여에 효과가 있었던 69명 중 39명은 내원 기간 동안 지속적인 효과를 나타내었으나 30명은 Carbamazepine에 대한 효과가 감소하였거나 부작용으로 인해 복합 투약을 시행하였거나 다른 약물로 교체 또는 신경외과로 의뢰하였다. 6. 54명(60%)의 환자에서 Carbamazepine 투여 후 현기증, 졸음, 오심, 혈구 감소, 피부 발진 등의 부작용이 발생하였으나 대부분 그 정도가 미약하거나 일시적이었고 11명의 환자가 부작용으로 인해 Carbaamzepien 투약을 중단하였다.

Keywords

References

  1. Merskey H, Bogduk N. Classification of Chronic Pain:Description of Chronic Pain Syndromes and Definitions of Pain Terms. Seattle: IASP Press;1994;59-71
  2. 이승우 외. 구강진단학. 5판, 서울, 1996, 신흥인터내셔날, pp. 164-166
  3. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition.Cephalagia 2004;24(suppl 1):9-160 https://doi.org/10.1111/j.1468-2982.2003.00824.x
  4. Sindrup SH, Jensen TS. Pharmacotherapy of trigeminal neuralgia. Clin J Pain 2002;18(1):22-27 https://doi.org/10.1097/00002508-200201000-00004
  5. Johns TP, Zakrzewska JM. Evidence-based approach to the medical management of trigeminal neuralgia. Br J Neurosurg 2007;21(3):253-261 https://doi.org/10.1080/02688690701219175
  6. Krafft RM. Trigeminal neuralgia. Am Fam Physician 2008;77(9):1291-1296
  7. Prasad S, Galetta S. Trigeminal neuralgia: historical notes and current concepts. Neurologist 2009;15:87-94 https://doi.org/10.1097/NRL.0b013e3181775ac3
  8. Cambell FG, Graham JG, Zilkha KJ. Clinical trial of carbamazepine(Tegretol) in trigeminal neuralgia. J Neurol Neurosurg Psychiatry 1966;29:265-267 https://doi.org/10.1136/jnnp.29.3.265
  9. Rockliff BW, Davis EH. Controlled sequential trials of carbamazepine in trigeminal neuralgia. Arch Neurol 1966;15:129-136 https://doi.org/10.1001/archneur.1966.00470140019003
  10. Killian JM, Fromm GH. Carbamazepine in the treatment of neuralgia. Arch Neurol 1968;19:129-136
  11. Nicol CF. A four year double-blind study of tegretol in facial pain. Headache 1969;9:54-57 https://doi.org/10.1111/j.1526-4610.1969.hed0901054.x
  12. Friis ML, Kristensen O, Boas J et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand. 1993;87(3):224-227 https://doi.org/10.1111/j.1600-0404.1993.tb04106.x
  13. Fromm GH, Terrence CF, Chattha AS. Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up. Ann Neurol 1984;15:240-244 https://doi.org/10.1002/ana.410150306
  14. Fromm GH, Terrence CF. Comparison of L-baclofen and racemic baclofen in trigeminal neuralgia.Neurology 1987;37:1725-1728 https://doi.org/10.1212/WNL.37.11.1725
  15. Katusic S, Beard CM, Bergstralh E et al. Incidence and Clinical Features of Trigeminal Neuralgia, Rochester, Minnesota, 1945-1984. Ann Neurol 1990;27:89-95 https://doi.org/10.1002/ana.410270114
  16. Barker FG II, Jannetta PJ, Bisonette DJ, Larkins MV, Jho HD. The long-term outcome of microvascular decompression for trigeminal neuralgia. N Engl J Med 1996;334:1077-1083 https://doi.org/10.1056/NEJM199604253341701
  17. Neto HS, Camilli JA, Marques MJ. Trigeminal neuralgia is caused by maxillary and mandibular nerve entrapment: Greater incidence of right-sided facial symptoms is due to the foramen rotundum and foramen ovale being narrower on the right side of the cranium. Med Hypotheses 2005;65(6):1179-1182 https://doi.org/10.1016/j.mehy.2005.06.012
  18. 고성희 외. 치과약리학. 5판, 서울, 대한나래출판사, pp.288-308
  19. Delcker A, Wilhelm H, Timmann D, Diener HC. Side effects from increased doses of carbamazepine on neuropsychological and posturographic parameters of humans. Eur Neuropsychopharmacol 1997;7(3):213-218 https://doi.org/10.1016/S0924-977X(97)00406-9
  20. Sobotka JL, Alexander B, Cook BL. A review of carbamazepine's hematologic reactions and monitoring recommendations. DICP 1990;24(12):1214-1219
  21. De Vriese AS, Philippe J, Van Renterghem DM, et al. Carbamazepine hypersensitivity syndrome: report of 4 cases and review of the literature. Medicine 1995;74(3):144-151 https://doi.org/10.1097/00005792-199505000-00004
  22. Ivry S, Shteinmintz D, Tabenkin H. Carbamazepine hypersensitivity symptoms. Harefuah 2000;138(7):545-547
  23. Taylor JC, Brauer S. Long-term treatment of trigeminal neuralgia with carbamazepine. Postgrad Med J 1981;57(663):16-18 https://doi.org/10.1136/pgmj.57.663.16